Research Article

In Vivo Antimalarial Activity of the Solvent Fractions of Fruit Rind and Root of Carica papaya Linn (Caricaceae) against Plasmodium berghei in Mice

Gemechu Zeleke,1 Dereje Kebebe,2 Eshetu Mulisa,1 and Fanta Gashe2

1Pharmacology Course Team, School of Pharmacy, Jimma University, P.O. Box 378, Jimma, Ethiopia
2Pharmaceutics Course Team, School of Pharmacy, Jimma University, P.O. Box 378, Jimma, Ethiopia

Correspondence should be addressed to Gemechu Zeleke; zelekecarii@yahoo.com

Received 1 August 2017; Accepted 22 November 2017; Published 17 December 2017

Academic Editor: José F. Silveira

Copyright © 2017 Gemechu Zeleke et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Currently, antimalarial drug resistance poses a serious challenge. This stresses the need for newer antimalarial compounds. Carica papaya is used traditionally and showed in vitro antimalarial activity. This study attempted to evaluate in vivo antimalarial activity of C. papaya in mice. Methods. In vivo antimalarial activity of solvent fractions of the plant was carried out against early P. berghei infection in mice. Parasitemia, temperature, PCV, and body weight of mice were recorded. Windows SPSS version 16 (one-way ANOVA followed by Tukey’s post hoc test) was used for data analysis. Results. The pet ether and chloroform fractions of C. papaya fruit rind and root produced a significant (p < 0.001) chemosuppressive effect. A maximum parasite suppression of 61.78% was produced by pet ether fraction of C. papaya fruit rind in the highest dose (400mg/kg/day). Only 400mg/kg/day dose of chloroform fraction of C. papaya root exhibited a parasite suppression effect (48.11%). But, methanol fraction of the plant parts produced less chemosuppressive effect. Conclusion. Pet ether fraction of C. papaya fruit rind had the highest antimalarial activity and could be a potential source of lead compound. Further study should be done to show the chemical and metabolomic profile of active ingredients.

1. Introduction

Even though a remarkable progress has been made, malaria remains a major health problem in Sub-Saharan Africa. It is endemic in 91 countries. The number of people infected with malaria in Sub-Saharan Africa is estimated to be 114 million in 2015. Children are especially vulnerable, accounting for more than two-thirds of global malaria deaths [1]. Malaria is also the major public health problem in Ethiopia. In Ethiopia, more than 75% of people live in malaria endemic areas, putting over 50 million people at risk of malaria. According to Federal Ministry of Health of Ethiopia 2015 report, about 1,165,843 cases of malaria were reported. In addition, it is the cause for 22,784 patients’ hospital admissions [1, 2].

However, safe and effective mode of treatment is needed to control malaria and its complications. The increasing antimalarial drug resistance, insecticide resistance, and behavioral changes in Anopheles vectors threaten effective antimalarial drug therapy and malaria control and elimination [3]. Artemisinin combination therapies (ACTs) are first-line treatment for uncomplicated falciparum malaria in all endemic countries, yet partial resistance to artemisinin has emerged in the Greater Mekong Subregion [4, 5].

The famous and potent antimalarial compounds quinine (obtained from Cinchona species) and artemisinin (obtained from Artemisia annua) are derived from plants [6]. Medicinal plants have been reported for their significant antimalarial activity and remain the main focus for scientists and researchers in the development of new antimalarial agents. Phytochemical compounds including alkaloids [7], phenolic compounds [8], anthraquinones [9], and flavonoids [10] are commonly implicated for the antimalarial activity of many plants. Carica papaya Linn belonging to family Caricaceae is commonly known as papaya in English, “papayyaa” in local language. Traditionally, Carica papaya leaves, root, and rind
are used for treatment of a wide range of ailments including malaria. Many scientific investigations have been conducted to evaluate the biological activities of various parts of Carica papaya including their fruits, shoots, leaves, rinds, seeds, roots, or latex. The plant possessed significant biological activities such as antioxidant [11], immunomodulatory [12], anti-inflammatory [13], analgesic [14], antitumor [15], wound healing [16], and antimicrobial [17].

Previous data showed that ethanol leaf extracts of Carica papaya exhibited a promising inhibitory activity against the CQ-sensitive strain of P. falciparum [18]. In addition, the petroleum ether extract of the rind of C. papaya had the highest in vitro antimalarial activity with IC50 of 15.19 μg/mL [19]. But, weak antiplasmodial activity was exhibited by the leaves and seeds of C. papaya [20]. There is no previous study showing in vivo antimalarial activity of the plant extracts.

Thus, based on in vitro efficacy and traditional claims, this study was aimed at evaluating in vivo antimalarial activity of the solvent fractions of Carica papaya fruit rind and root in mice.

2. Methods

2.1. Collection and Authentication of Plant Materials. The fresh Carica papaya fruits and roots were collected from near Jimma town, Southwest Ethiopia, in August 2016. The plant material was authenticated by a taxonomist at the Ethiopian National Herbarium, Addis Ababa University. The specimen was deposited for future reference with voucher number JUGZ01/2016 at the National Herbarium, College of Natural Sciences, Addis Ababa University.

2.2. Preparation Solvent Fractions. The fresh Carica papaya Linn fruit rind/peel and roots were air-dried at room temperature under shade and pulverized into powder using pestle and mortar. The solvent fractions of C. papaya fruit rind and root were obtained by sequential soxhlet extraction with petroleum ether, chloroform, and then methanol in increasing polarity [19]. 40 grams of the powdered plant material was weighed and placed in the extraction thimble containing thimble. This extraction process was continued exhaustively until clear solution in the thimble was siphoned into the solvent flask. Then, the petroleum ether fraction was filtered with Whatman number 1 filter paper and the solvent was removed by placing in oven adjusted at a temperature less than 40°C. The marc of the petroleum ether based extraction was collected and dried at room temperature to remove petroleum ether. The dried left marc was extracted using absolute chloroform following the same procedure as described for petroleum ether extraction to get the chloroform fraction. Finally, the marc of chloroform fraction was collected and dried at room temperature. Then, the whole dried marc was further extracted with methanol with the same procedure indicated above. Each of the fractions was separately stored in screw capped vials in refrigerator until used for the study.

2.3. Experimental Animals. Healthy male Swiss Albino mice (8–12 weeks, weighing 25–33 grams) bred and maintained at Ethiopian Public Health Institute were used. The animals were kept in cages and housed in a standard animal house under natural 12/12h light dark cycle at room temperature, the animal house of School of Veterinary Medicine, Jimma University. They were maintained on standard pelleted diet and water ad libitum. All mice were acclimatized for one week before the study. This study was approved by the ethical review board of college of health science of Jimma University with a reference number HRPGC/578/2015. All experiments were conducted in accordance with the internationally accepted guidelines on laboratory animal use, care, and handling [21].

2.4. Acute Toxicity Tests. The acute toxicity studies were conducted as per the OECD guidelines 425. Acute oral toxicity of each of the solvent fractions was evaluated in healthy female mice aged of 6–8 weeks. Five female mice were fasted for three hours and orally given a dose of 2000 mg/kg of the solvent fractions. The mice were observed for lacrimation, hair erection, behavioral change, reduction in their motor, feeding activities, and mortality for three hours and followed for 24 hours and/or 14 days [22].

2.5. Parasite Inoculation. Chloroquine sensitive P. berghei ANKA strain obtained from Ethiopian Public Health Institute and maintained at animal house facility was used. For the parasite maintenance serial passage of blood from infected mice to noninfected ones was made. A donor mouse with a parasitemia of approximately 30% was sacrificed and blood collected in a Petri-dish containing 2% trisodium citrate as anticoagulant. The blood was then diluted with 0.9% normal saline. Each mouse used in the experiment was inoculated intraperitoneal with 0.2 ml of 1 × 10^7 P. Berghei infected red blood cells [23].

2.6. In Vivo Antimalarial Activity Study. In vivo antiplasmodial activity of the plant extract against early P. berghei infection was carried out according to the method described by Peter et al. (1975). Based on acute toxicity test, three doses (100, 200, and 400 mg/kg/day) were selected for the in vivo antimalarial study of the solvent fractions [24].

After parasite inoculation, 30 mice were randomly assigned into five groups (three treatment groups and two controls), 6 mice per group. The negative control group was treated with the vehicle 2% Tween 80. Likewise, positive control group was treated with standard drug chloroquine 25 mg/kg/day. The remaining three groups received three different doses (100, 200, and 400 mg/kg/day) of the plant extracts. The doses were administered orally at a volume of 10 ml/kg. The mice were treated after three hours of infection and continued for three days.

Weight, rectal temperature, and packed cell volume (PCV) were recorded just before infection and on day four postinfection. On day four, a thin blood film was prepared.
Table 1: Effect of the solvent fractions of C. papaya fruit rind on parasitemia and survival of P. berghei infected mice on 4-day Peter’s suppression test.

| Treatment                  | Dose in mg/kg/day | % parasitemia | % chemosuppression | Survival date |
|----------------------------|------------------|---------------|--------------------|---------------|
| Petroleum ether fraction   | 100              | 40.45 ± 2.1   | 23.0±2.3,2.d,2.e    | 8.67 ± 0.52   |
|                            | 200              | 34.48 ± 4.9   | 34.38±2.3,2.e      | 8.83 ± 0.75   |
|                            | 400              | 20.08 ± 2.4   | 61.76±2.3,3.d      | 10.33 ± 1.03   |
| Chloroform fraction        | 100              | 46.92 ± 4.7   | 10.72±2.3,3.d,2.e  | 8.33 ± 0.52   |
|                            | 200              | 39.83 ± 3.3   | 24.20±2.3,3.e      | 8.67 ± 0.82   |
|                            | 400              | 32.77 ± 1.61  | 37.65±2.3,3.d      | 9.5 ± 1.05    |
| Methanol fraction          | 100              | 48.25 ± 4.38  | 8.18±3.3           | 7.67 ± 0.52   |
|                            | 200              | 43.53 ± 3.25  | 17.16±2.3,3        | 8.50 ± 0.55   |
|                            | 400              | 42.88 ± 4.88  | 18.39±3.3,3        | 8.17 ± 0.75   |
| Vehicle                    | 1 ml             | 52.55 ± 5.6   | -                  | 7.83 ± 0.75   |
| Chloroquine                | 25               | 0             | 100±3,3,e           | 30.00 ± 0.00   |

Data are expressed as mean ± SEM; n = 6; *compared to negative control (vehicle; 2% Tween 80), †compared to chloroquine 25 mg/kg, ‡compared to 100 mg/kg/day of the fraction, §compared to 200 mg/kg/day of the fraction, ‡‡compared to 400 mg/kg/day of the fraction; ³p < 0.05; ⁴p < 0.01; ⁵p < 0.001.

2.7. Determination of Packed Cell Volume. For packed cell volume (PCV) determination, blood was drawn from the tail of the different group of mice using heparinized capillary tubes before infection and on day 4 after infection. The tubes were filled with blood up to (3/4)th of their volume and sealed at the dry end with sealing clay. The tubes were then placed in hematocrit centrifuge with the sealed end outwards and centrifuged for 5 min at 5,000 rpm [25].

Packed Cell Volume

\[
\text{Packed Cell Volume} = \frac{\text{Volume of erythrocytes in a given volume of blood}}{\text{Total blood volume}} \times 100.
\]

2.8. Phytochemical Screening Test. The solvent fractions of root and rind of Carica papaya were qualitatively screened for the presence of secondary metabolites. Thus, tests for alkaloids, flavonoids, terpenoids, phenolic compounds, tannins, saponins, anthraquinones, and cardiac glycosides were performed using standard test procedures [26, 27].

2.9. Data Analysis. The data was analyzed using windows software SPSS version 16 and expressed as mean ± standard error of mean (M ± SEM). Statistical significance was determined by one-way analysis of variance (ANOVA), followed by Tukey post hoc test to compare the measured parameters (parasitemia suppression, weight, rectal temperature, and survival time) within and between groups. The analysis was performed with 95% confidence interval and p values less than 0.05 were considered to be statistically significant.

3. Result

The findings from the four-day suppressive test showed that petroleum ether of Carica papaya fruit rind has a considerable antiplasmodial activity in vivo against P. berghei on early infections. In this study, the petroleum ether fraction of C. papaya fruit rind produced a dose dependent chemosuppressive effect at three doses evaluated (100, 200, and 400 mg/kg/day), with a chemosuppression of 23.03%, 34.38%, and 61.78%, respectively (Table 1). At all dose levels evaluated, the three fractions produced a statistically significant (p < 0.001) parasite suppression as compared to negative control. The highest chemosuppressive effect (61.78%) was exhibited by petroleum ether fraction of C. papaya fruit rind at 400 mg/kg/day dose.

However, a mild chemosuppression was produced by the methanol fraction of C. papaya fruit rind. On the other hand, the standard drug, chloroquine, caused chemosuppression of 100%. Compared to negative control, only the highest dose (400 mg/kg/day) of petroleum ether (p < 0.001) and chloroform (p < 0.05) fractions caused a statistically significant prolongation of survival time. However, the methanol...
fraction was not associated with significant prolongation of survival time when compared with the negative control.

As shown in Table 2, C. papaya root fractions produced a dose dependent and statistically significant (p < 0.001) chemosuppressive effect at the three doses evaluated (100, 200, and 400 mg/kg/day). The parasite suppression by petroleum ether fraction was 21.85%, 31.53%, and 43.77% for 100, 200, and 400 mg/kg/day doses, respectively. Likewise, the parasite suppression by chloroform fraction was 9.77%, 25.25%, and 48.11% for 100, 200, and 400 mg/kg/day doses. The 400 mg/kg/day dose of the ether and chloroform fractions produced the highest parasite suppression relative to the other doses.

Both 200 and 400 mg/kg/day doses of the ether fraction caused statistically significant (p < 0.05) survival time prolongation effect, with the mean survival time of 9.83 and 10.17 days, respectively. Similarly, 400 mg/kg/day dose of the chloroform fraction exhibited statistically significant (p < 0.01) survival time (10.17±0.75 days) prolongation effect compared to the negative control group. This effect was still by much lower (p < 0.001) than that attained by chloroquine (30 ± 0.00).

Analysis of PCV change (between day 0 and day 4 after infection) shows that the higher two doses (200 and 400 mg/kg/day) of petroleum ether fraction of C. papaya fruit rind significantly (p < 0.01) prevented reduction in PCV as compared to the negative control. Likewise, only the highest administered dose (400 mg/kg/day) of chloroform fraction of C. papaya fruit rind significantly (p < 0.01) prevented reduction in PCV (Table 3, Figure 1).

The solvent fractions of C. papaya fruit rind exhibited a significant protection against body temperature reduction on day 4. Analysis of percent of body temperature change, between days 0 and 4, indicated that P. berghei infected mice treated with the three doses of the pet ether and chloroform fractions showed a statistically significant (p < 0.01) difference when compared to negative control (Table 4). The attenuation of the reduction in body temperature produced

Table 2: Effect of the solvent fractions of C. papaya root on parasitemia and survival of infected mice with P. berghei on 4-day Peter's suppression test.

| Treatment                  | Dose mg/kg/day | % parasitemia | % chemosuppression | Survival date |
|----------------------------|----------------|---------------|--------------------|--------------|
| Petroleum ether fraction   | 100            | 41.07 ± 2.55  | 21.85b,c,d,2        | 8.00 ± 0.63  |
|                            | 200            | 35.98 ± 3.67  | 31.53b,c,d,2        | 9.17 ± 0.41  |
|                            | 400            | 29.55 ± 4.42  | 43.77b,c,d,2        | 9.83 ± 1.33  |
| Chloroform fraction        | 100            | 47.42 ± 1.94  | 9.77a,b,c,d,2       | 7.83 ± 0.41  |
|                            | 200            | 39.28 ± 1.53  | 25.25a,b,c,d,2      | 8.83 ± 0.79  |
|                            | 400            | 27.27 ± 3.36  | 48.11a,b,c,d,2      | 10.17 ± 0.75 |
| Methanol fraction          | 100            | 47.13 ± 4.39  | 10.31b               | 7.83 ± 0.75  |
|                            | 200            | 47.22 ± 4.97  | 10.15b               | 8.33 ± 1.03  |
|                            | 400            | 39.08 ± 2.76  | 25.63a,b,c,d,2      | 9.00 ± 0.89  |
| Vehicle                    | 1 ml           | 52.55 ± 5.6   | -                  | 7.83 ± 0.75  |
| Chloroquine                | 25             | 0.00 ± 0.00   | 100                | 30.00 ± 0.00 |

Data are expressed as mean ± SEM; n = 6; a compared to negative control (vehicle; 2% Tween 80), b compared to chloroquine 25 mg/kg, c compared to 100 mg/kg/day of the fraction, d compared to 200 mg/kg/day of the fraction, and e compared to 400 mg/kg/day of the fraction; 1 p < 0.05; 2 p < 0.01; 3 p < 0.001.

Table 3: Effect of the solvent fractions of Carica papaya rind on packed cell volume (PCV) of P. berghei infected mice on 4-day Peter's suppression test.

| Treatment group            | Dose mg/kg/day | Day 0       | Packed cell volume | % change |
|----------------------------|----------------|-------------|--------------------|----------|
| Pet ether fraction         | 100            | 57.7 ± 2.34 | 56.0 ± 2.83        | −3.02    |
|                            | 200            | 58.2 ± 2.04 | 57.0 ± 1.67        | −2.09    |
|                            | 400            | 57.3 ± 2.42 | 57.2 ± 2.40        | −0.29    |
| Chloroform fraction        | 100            | 56.3 ± 1.97 | 53.7 ± 2.94        | −5.09    |
|                            | 200            | 56.3 ± 1.50 | 54.3 ± 2.94        | −3.85    |
|                            | 400            | 55.0 ± 1.09 | 54.7 ± 1.21        | −0.62    |
| Methanol fraction          | 100            | 57.0 ± 1.09 | 55.7 ± 2.34        | −2.49    |
|                            | 200            | 56.0 ± 1.79 | 56.0 ± 2.19        | −0.04    |
|                            | 400            | 56.3 ± 1.50 | 56.0 ± 2.83        | −0.70    |
| Vehicle                    | 1 ml           | 56.0 ± 1.79 | 50.67 ± 3.26       | −10.79   |
| Chloroquine                | 25             | 57.0 ± 1.55 | 58.00 ± 2.10       | 1.69     |

Data are expressed as mean ± SEM; n = 6; a compared to negative control (vehicle; 2% Tween 80); 1 p < 0.05; 2 p < 0.01. Day 0 = pretreatment value on day 0. Day 4 = posttreatment value on day four.
by 200 and 400 mg/kg/day doses of pet ether fraction of *C. papaya* fruit rind had a comparable effect to chloroquine. In chloroquine treated group, no significant change in both body temperature and PCV was observed. On the other hand, the chloroform fraction (at all doses evaluated) of *C. papaya* fruit rind averted loss of body weight associated with infection compared to negative control. In contrast, body weight reduction caused by inoculation of the parasite was not significantly prevented by the ether fraction. Percent PCV change analysis, between days 0 and 4, revealed that the three doses (100 mg/kg with $p < 0.05$, 200 mg/kg with $p < 0.01$, and 400 mg/kg with $p < 0.001$) of petroleum ether fraction of *C. papaya* root significantly attenuated the PCV reduction compared with the negative control. Similarly, the 200 mg/kg ($p < 0.05$) and 400 mg/kg ($p < 0.001$) doses of chloroform fraction showed a statistically significant PCV protection effect unlike methanol fraction (Table 5, Figure 2).

![Figure 1: Effect of the solvent fractions of *C. papaya* fruit rind on packed cell volume (PCV) of *P. berghei* infected mice on 4-day Peter's suppression test.](image)

![Figure 2: Percent PCV change analysis, between days 0 and 4, revealed that the three doses of petroleum ether fraction of *C. papaya* root significantly attenuated the PCV reduction compared with the negative control. Similarly, the 200 mg/kg ($p < 0.05$) and 400 mg/kg ($p < 0.001$) doses of chloroform fraction showed a statistically significant PCV protection effect unlike methanol fraction.](image)

**Table 4:** Effect of the solvent fractions of *Carica papaya* rind on body temperature and weight of *P. berghei* infected mice on 4-day Peter’s suppression test.

| Treatment          | Dose mg/kg | Day 0 Temperature | % change | Day 0 Weight | % change |
|--------------------|------------|-------------------|----------|--------------|----------|
| Pet ether fraction | 100        | 37.1 ± 0.07       | 36.6 ± 0.33 | −1.37a | 27.3 ± 1.03 | 26.3 ± 1.97 | −4.15 |
|                    | 200        | 37.1 ± 0.13       | 36.9 ± 0.43 | −0.66a | 22.0 ± 1.90 | 23.5 ± 1.22 | 6.41a |
|                    | 400        | 37.1 ± 0.07       | 36.9 ± 0.25 | −0.41a | 26.0 ± 0.89 | 25.8 ± 1.17 | −0.72a |
| Chloroform fraction| 100        | 37.2 ± 0.14       | 35.7 ± 0.29 | −1.27a | 24.2 ± 2.14 | 23.5 ± 2.17 | −3.01 |
|                    | 200        | 37.1 ± 0.12       | 37.0 ± 0.32 | −0.36a | 26.5 ± 2.51 | 26.7 ± 3.20 | 0.30a |
|                    | 400        | 37.1 ± 0.08       | 36.9 ± 0.13 | −0.41a | 24.7 ± 1.97 | 25.0 ± 1.55 | 1.23a |
| Methanol fraction  | 100        | 37.1 ± 0.13       | 35.5 ± 0.34 | −1.67a | 25.5 ± 1.05 | 24.2 ± 1.33 | −5.66a |
|                    | 200        | 37.1 ± 0.15       | 35.7 ± 0.29 | −1.09a | 23.8 ± 0.98 | 24.3 ± 1.21 | 1.91a |
|                    | 400        | 37.0 ± 0.08       | 35.6 ± 0.55 | −1.29a | 24.5 ± 1.22 | 24.7 ± 1.21 | 0.62a |
| Vehicle            | 1ml        | 37.1 ± 0.14       | 34.05 ± 0.78 | −5.89 | 25.33 ± 2.16 | 22.3 ± 2.25 | −13.66 |
| Chloroquine        | 25         | 37.1 ± 0.39       | 37.30 ± 0.32 | 0.41a | 33.3 ± 5.05 | 34.3 ± 5.35 | 3.16 |

Data are expressed as mean ± SEM; $n = 6$; *a* compared to negative control (vehicle; 2% Tween 80); $^1p < 0.05$; $^2p < 0.01$; $^3p < 0.001$. Day 0 = pretreatment value on day 0. Day 4 = posttreatment value on day four.
Table 5: Effect of the solvent fractions of *Carica papaya* root on PCV, body temperature, and weight of *P. berghei* infected mice on 4-day Peter's suppression test.

| Treatment group          | Dose mg/kg/day | Day 0          | Day 4          | % change |
|--------------------------|----------------|----------------|----------------|----------|
| Petroleum ether fraction | 100            | 55.3 ± 2.94    | 53.5 ± 1.22    | −3.45    |
|                          | 200            | 55.5 ± 1.52    | 54.3 ± 3.44    | −2.34    |
|                          | 400            | 56.3 ± 1.97    | 55.5 ± 1.52    | −1.51    |
| Chloroform fraction      | 100            | 55.7 ± 1.50    | 52.17 ± 2.23   | −6.81    |
|                          | 200            | 55.0 ± 1.09    | 52.7 ± 1.63    | −4.47    |
|                          | 400            | 54.7 ± 1.03    | 53.5 ± 2.17    | −2.28    |
| Methanol fraction        | 100            | 56.0 ± 1.26    | 51.7 ± 1.50    | −8.41    |
|                          | 200            | 55.0 ± 1.09    | 49.8 ± 2.23    | −10.50   |
|                          | 400            | 55.7 ± 1.50    | 54 ± 1.79      | −3.11    |
| Vehicle                  | 1 ml           | 56.0 ± 1.79    | 50.7 ± 3.27    | −10.79   |
| Chloroquine              | 25             | 56.0 ± 1.55    | 56.0 ± 2.10    | 1.69     |

Data are expressed as mean ± SEM; *n* = 6; *a* compared to negative control (vehicle; 2% Tween 80); *p* < 0.05; *p* < 0.01; *p* < 0.001. Day 0 = pretreatment value on day 0. Day 4 = posttreatment value on day four.

Analysis of percent of body temperature change, between days 0 and 4, revealed that at the evaluated doses the three fractions *C. papaya* root showed a statistically significant (*p* < 0.05) difference when compared to negative control. This difference was not significant when compared with chloroquine treated group. On the other hand, the effect of petroleum ether and chloroform fractions on body weight was not dose dependent and consistent. As indicated in Table 6, the lower doses of *C. papaya* root solvent fractions produced a significant (*p* < 0.05) parasite induced body weight reduction.

3.1. Phytochemical Screening. In the qualitative phytochemical analysis, the solvent fractions of fruit rind and root of *Carica papaya* showed the presence of secondary metabolites such as alkaloids, flavonoids, polyphenols, tannins, and terpenoids as indicated in Table 7.

4. Discussion

Antimalarial drug resistance remains a major challenge and continued to emerge creating an obstacle in malaria control and elimination [5, 28]. At present, developing novel
approaches and new alternative antimalarial drugs is pivotal to combat the disease [29]. From history, medicinal plants are endowed with active antimalarial compounds as artemisinin is obtained from Artemisia annua and quinine from Cinchona bark [30]. *In vivo* evaluations of antimalarial activity begin with the use of the rodent malaria parasite. In addition, *in vivo* studies take into account any prodruge effect and the role of immune system in controlling malaria infection unlike *in vitro* ones [23]. Accordingly, this study evaluated the *in vivo* antimalarial activity of solvent fractions of *Carica papaya* root and fruit rind using the 4-day suppressive test, which mainly evaluates the antimalarial activity of candidates on early infections, against *P. berghei* in mice. In acute toxicity studies, the observation of no death or sign of toxicity with an oral dose of 2000 mg/kg of the fractions indicated the solvent fractions are safe for use.

In this study, all the solvent fractions of *Carica papaya* root and fruit rind exhibited a statistically significant (*p* < 0.001) and dose dependent parasite suppression effect on early infections (Tables 1 and 2). A maximum parasite suppression of 61.78% was produced by petroleum ether fraction of *Carica papaya* fruit rind in the highest dose (400 mg/kg/day), with the longest survival time compared to other fractions treated mice and negative control. Likewise, chloroform fraction of *Carica papaya* root exhibited a higher chemosuppression effect of 48.11% at 400 mg/kg/day dose. The parasite suppression exhibited by these solvent fractions was comparable with similar studies done on *D. angustifolia* [25], *Lophira alata* [31], and *Parkia biglobosa* [32]. But, a weak parasite suppression effect was exhibited by methanol fraction of both root and fruit rind of this plant.

Malaria infected mice suffer from anemia because of erythrocyte destruction, either by malaria multiplication or by spleen reticuloendothelial cell action [33]. An ideal antimalarial candidate should prevent anemia secondary to preventing hemolysis, body weight loss, and body temperature reduction in mice. In this study, a significant attenuation of PCV and body temperature reduction effect was observed by petroleum ether and chloroform fractions at 200 and 400 mg/kg doses. This was also comparable to standard drug chloroquine. The effect of the solvent fractions on body weight was variable and produced inconsistent protection. This might be due to the nature of the ingredients present in the fractions causing apatite suppression.

*In vivo* antimalarial activity can be classified as moderate, good, and very good if an extract displayed percent of parasite suppression equal to or greater than 50% at a dose of 500 mg, 250 mg, and 100 mg/kg body weight.

### Table 6: Effect of the solvent fractions of *C. papaya* root on body temperature and body weight of *P. berghei* infected mice on 4-day Peter’s suppression test.

| Treatment group                  | Dose mg/kg/day | Temperature Day 0 | Temperature Day 4 | % change | Weight Day 0 | Weight Day 4 | % change |
|----------------------------------|----------------|------------------|------------------|----------|--------------|--------------|----------|
| Petroleum ether fraction         | 100            | 37.2 ± 0.15      | 35.9 ± 0.23      | −0.68 ± 0.001 | 24.7 ± 3.26 | 24.2 ± 3.12 | −2.00 ± 0.001 |
|                                  | 200            | 37.1 ± 0.12      | 37.0 ± 0.13      | −0.18 ± 0.001 | 28.3 ± 2.25 | 27.5 ± 1.76 | −3.04 ± 0.001 |
|                                  | 400            | 37.1 ± 0.09      | 37.0 ± 0.19      | −0.22 ± 0.001 | 22.2 ± 1.94 | 20.8 ± 2.99 | −7.36 ± 0.001 |
| Chloroform fraction              | 100            | 37.1 ± 0.10      | 35.5 ± 0.38      | −1.70 ± 0.001 | 20.2 ± 1.17 | 19.5 ± 1.05 | −3.52 ± 0.001 |
|                                  | 200            | 37.2 ± 0.07      | 36.9 ± 0.10      | −0.63 ± 0.001 | 20.5 ± 1.38 | 19.8 ± 1.72 | −3.75 ± 0.001 |
|                                  | 400            | 37.1 ± 0.12      | 36.9 ± 0.16      | −0.50 ± 0.001 | 22.7 ± 1.37 | 21.5 ± 1.52 | −5.62 ± 0.001 |
| Methanol fraction                | 100            | 37.1 ± 0.12      | 34.5 ± 0.35      | −1.60 ± 0.001 | 21.2 ± 1.60 | 22.5 ± 1.64 | 1.39 ± 0.001  |
|                                  | 200            | 37.1 ± 0.18      | 34.6 ± 0.27      | −1.37 ± 0.001 | 21.0 ± 0.89 | 18.8 ± 1.94 | −12.32 ± 0.001 |
|                                  | 400            | 37.1 ± 0.12      | 35.7 ± 0.29      | −1.09 ± 0.001 | 20.3 ± 1.63 | 19.8 ± 1.72 | −2.60 ± 0.001 |
| Vehicle                          | 1 ml           | 37.1 ± 0.13      | 34.0 ± 0.78      | −5.89 ± 0.001 | 25.3 ± 2.16 | 22.3 ± 2.25 | −13.66 ± 0.001 |
| Chloroquine                      | 25             | 37.1 ± 0.39      | 37.3 ± 0.32      | 0.41 ± 0.001  | 33.3 ± 5.05 | 34.3 ± 5.35 | 1.61 ± 0.001  |

Data are expressed as mean ± SEM; *n* = 6; *p* compared to negative control (vehicle; 2% Tween 80); *p* < 0.05; *p* < 0.001. Day 0 = pretreatment value on day 0. Day 4 = posttreatment value on day four.

### Table 7: Qualitative phytochemical screening of the solvent fractions of fruit rind and root of *Carica papaya*.

| Secondary metabolites | *C. papaya* fruit rind fractions | *C. papaya* root fractions |
|-----------------------|----------------------------------|---------------------------|
|                       | Pet ether | Chloroform | Methanol | Pet ether | Chloroform | Methanol |
| Alkaloids              | +         | +          | −        | +         | +          | +        |
| Flavonoids            | +         | +          | −        | +         | +          | −        |
| Polyphenols           | +         | +          | +        | +         | +          | −        |
| Tannins               | +         | +          | +        | +         | +          | +        |
| Terpenoids            | +         | +          | +        | +         | +          | +        |
| Cardiac glycosides    | −         | −          | −        | −         | −          | −        |
| Saponin               | −         | −          | +        | −         | −          | −        |

Note. + indicates the presence and – indicates absence of particular metabolites.
per day, respectively [34, 35]. Based on this classification, the petroleum ether fraction of *Carica papaya* fruit rind and chloroform fraction of *Carica papaya* root exhibited a moderate antiplasmodial activity.

In this study, the pet ether fraction of *Carica papaya* fruit rind produced a promising in vivo antiplasmodial activity. This result was in agreement with *in vitro* antiplasmodial activity of pet ether (IC$_{50}$ = 15.19 µg/mL) and methanol (IC$_{50}$ > 100 µg/mL) fractions of *C. papaya* fruit rind in previous study [19]. In another study, the leaf extract of *C. papaya* produced antiplasmodial activity with IC$_{50}$ of 46.23 µg/mL [20]. This signifies that the pet ether fraction of *C. papaya* fruit rind had the highest antimalarial activity relative to the other fractions and the plant parts. This is attributed to the possible presence of the active metabolites. On phytochemical screening, terpenoids, flavonoids, alkaloids, and phenols are present in both petroleum ether and chloroform fractions that might be responsible for the observed antimalarial activity. These phytochemicals might also exert a synergistic antiplasmodial effect. But, weak antimalarial activity by the methanol fraction may be due to the presence of trace active constituents in the administered dose.

This finding may be an indicator for the presence of potential compounds with higher antimalarial activity in the petroleum ether fraction of *C. papaya* fruit rind. From this study, the active antimalarial compound found in *C. papaya* fruit rind is possibly nonpolar or semipolar in nature. Moreover, there may be a commercial potential in extracting the active compound from this plant, which grows abundantly throughout the tropics, the rind of which is discarded as waste.

5. Conclusion

The higher dose of pet ether and chloroform fraction of *C. papaya* fruit rind and root exhibited a moderate antiplasmodial effect with the longest survival time compared to negative control. From this finding, the petroleum ether fraction of *C. papaya* fruit rind had the highest antimalarial activity and could be targeted as potential source of lead compound in the development of new antimalarial agent. Therefore, further study should be done on pet ether fraction of *C. papaya* fruit rind to show the chemical and metabolomic profile of active ingredients from this plant.

Additional Points

*Availability of Data and Materials.* The complete data are all contained within the paper and are also available from the corresponding author on reasonable request.

Ethical Approval

This experimental study was approved by Institutional Review Board (IRB) of College of Health Sciences of Jimma University by the letter written in Reference no. HRPGC/578/2015 by the Ethical Review Committee.

Conflicts of Interest

The authors declare that there are no conflicts of interest to disclose.

Authors’ Contributions

Gemechu Zeleke and Fanta Gashe conducted the actual study, the statistical analysis, and write-up of the manuscript. Dereje Kebebe and Eshetu Mulisa were involved in developing the idea and designing the study. All authors approved the submitted version of the manuscript.

Acknowledgments

The financial support from College of Health Sciences of Jimma University is gratefully acknowledged. The authors also would like to acknowledge Ethiopian National Herbarium of Addis Ababa University for the plant identification.

References

[1] World Health Organization: World Malaria Report, Geneva, Switzerland, 2016, 54-61.
[2] Federal Ministry of health, Health and health Related Indicators in Ethiopia. Addis Ababa, 2015, 35-38.
[3] S. Sougoufara, S. Doucouré, P. M. B. Sembène, M. Harry, and C. Sokhna, "Challenges for malaria vector control in sub-Saharan Africa: Resistance and behavioral adaptations in Anopheles populations," *Journal of Vector Borne Diseases*, vol. 54, no. 1, pp. 4–15, 2017.
[4] E. A. Ashley, M. Dhorda, R. M. Fairhurst, C. Amaratunga, P. Lim, and P. Suon, "Spread of Artemisinin Resistance in *Plasmodium falciparum* Malaria," *The New England Journal of Medicine*, vol. 371, pp. 411–423, 2014.
[5] D. Menard and A. Dondorp, "Antimalarial Drug Resistance: A Threat to Malaria Elimination," *Cold Spring Harbor Perspectives in Medicine*, vol. 7, no. 7, Article ID a025619, 2017.
[6] T. J. Schmidt, S. A. Khalid, A. J. Romana et al., "The potential of secondary metabolites from plants as drugs or leads against protozoan neglected diseases - Part II," *Current Medicinal Chemistry*, vol. 19, no. 14, pp. 2176–2228, 2012.
[7] M. Frederich, M. Tits, and L. Angenot, "Potential antimalarial activity of indole alkaloids," *Transactions of the Royal Society of Tropical Medicine and Hygiene*, vol. 102, no. 1, pp. 11–19, 2008.
[8] J. Bero, M. Frédérich, and J. Quetin-Leclercq. "Antimalarial compounds isolated from plants used in traditional medicine," *Journal of Pharmacy and Pharmacology*, vol. 61, no. 11, pp. 1401–1433, 2009.
[9] S. S. Mahajan, V. R. Kamath, and S. S. Ghatpande, "Synergistic antimalarial activity of ketones with rutigalol and vitamin C," *Parasitology*, vol. 131, no. 4, pp. 459–466, 2005.
[10] F. Ntie-Kang, P. A. Onguéné, L. L. Lifongo, J. C. Ndom, W. Sippl, and L. M. Mbaze, "The potential of anti-malarial compounds derived from African medicinal plants, part II: A pharmacological evaluation of non-alkaloids and non-terpenoids," *Malaria Journal*, vol. 13, no. 1, article no. 81, 2014.
[11] A. M. Maisarah, B. Nurul Amira, R. Asmah, and O. Fauziah, "Antioxidant analysis of different parts of Carica papaya," *International Food Research Journal*, vol. 20, no. 3, pp. 1043-1048, 2013.
[12] K. S. Ramesh, R. S. Kambimath, and N. Venkatesan, “Study of immunomodulatory activity of aqueous extract of Carica papaya in Wistar rats,” *National Journal of Physiology, Pharmacy and Pharmacology*, vol. 6, no. 5, pp. 442–444, 2016.

[13] L. U. Amazu, C. C. A. Azikiwe, C. J. Njoku et al., “Anti-inflammatory activity of the methanolic extract of the seeds of Carica papaya in experimental animals,” *Asian Pacific Journal of Tropical Medicine*, vol. 3, no. 11, pp. 884–886, 2010.

[14] P. Hasimun, S. Suwendar, and G. Ernasari, “Analgetic Activity of Papaya (Carica papaya L.) Leaves Extract,” *Procedia Chemistry*, vol. 13, pp. 147–149, 2014.

[15] N. Otsuki, N. H. Dang, E. Kumagai, A. Kondo, S. Iwata, and C. Morimoto, “Aqueous extract of *Carica papaya* leaves exhibits anti-tumor activity and immunomodulatory effects,” *Journal of Ethnopharmacology*, vol. 127, no. 3, pp. 760–767, 2010.

[16] P. Tiwari, K. Kumar, R. Panik, A. Pandey, A. Pandey, and P. K. Sahu, “Evaluation of aqueous extract of roots of carica papaya on wound healing activity in albino rats,” *Journal of Chemical and Pharmaceutical Research*, vol. 3, no. 4, pp. 291–295, 2011.

[17] P. O. Orhue and A. R. M. Momoh, “Antibacterial activities of different solvent extracts of carica papaya fruit parts on some gram positive and gram negative organisms,” *International Journal of Herbs and Pharmacological Research*, vol. 2, no. 4, pp. 42–47, 2013.

[18] K. Kovendant, K. Murugan, C. Panneerselvam et al., “Antimalarial activity of *Carica papaya* (Family: Caricaceae) leaf extract against *Plasmodium falciparum*,” *Asian Pacific Journal of Tropical Disease*, vol. 2, no. 1, pp. S306–S311, 2012.

[19] G. P. Bhat and N. Surolia, “In vitro antimalarial activity of extracts of three plants used in the traditional medicine of India,” *The American Journal of Tropical Medicine and Hygiene*, vol. 65, no. 4, pp. 304–308, 2001.

[20] S. Ravikumar, S. J. Inbaneson, and P. Suganthi, “In vitro antiplasmodial activity of chosen terrestrial medicinal plants against *Plasmodium falciparum*,” *Asian Pacific Journal of Tropical Biomedicine*, vol. 2, no. 1, pp. S252–S256, 2012.

[21] National Research Council., *Guide for the Care and Use of Laboratory Animals*, The National Academies Press, Washington, DC, USA, 8th edition, 2011, http://www.national-academies.org/.

[22] The Organization of Economic Co-operation and Development., *The OECD Guideline for Testing of Chemical 425, Acute Oral Toxicity*, France, 2001.

[23] D. A. Fidock, P. J. Rosenthal, S. L. Croft, R. Brun, and S. Nwaka, “Antimalarial drug discovery: Efficacy models for compound screening,” *Nature Reviews Drug Discovery*, vol. 3, no. 6, pp. 509–520, 2004.

[24] W. Peter, H. Portus, and L. Robinson, “The four-day suppressive in vivo antimalarial test,” *Annals of Tropical Medicine and Parasitology*, vol. 69, pp. 155–171, 1975.

[25] W. Amelo, P. Nagpal, and E. Makonnen, “Antiplasmodial activity of solvent fractions of methanolic root extract of *Dodonaea angustifolia* in *Plasmodium berghei* infected mice,” *BMC Complementary and Alternative Medicine*, vol. 14, no. 1, article no. 462, 2014.

[26] R. N. S. Yadav and M. Agarwala, “Phytochemical analysis of some medicinal plants,” *Journal of Phytochemistry*, vol. 3, no. 12, pp. 10–14, 2011.

[27] G. Ayoola, H. Coker, S. Adesegun et al., “Phytochemical screening and antioxidant activities of some selected medicinal plants used for malaria therapy in Southwestern Nigeria,” *Tropical Journal of Pharmaceutical Research*, vol. 7, no. 3, pp. 1019–1024, 2008.

[28] M. Imwong, K. Suwannasirin, C. Kunasol et al., “The spread of artesinin-resistant *Plasmodium falciparum* in the Greater Mekong subregion: a molecular epidemiology observational study,” *The Lancet Infectious Diseases*, vol. 17, no. 5, pp. 491–497, 2017.

[29] A. S. Bhagavathula, A. A. Elnour, and A. Shehab, “Alternatives to currently used antimalarial drugs: In search of a magic bullet,” *Infectious Diseases of Poverty*, vol. 5, no. 1, article no. 103, 2016.

[30] I. M. Maje, J. A. Anuka, and I. M. Hssaini, “Evaluation of the anti-malarial activity of the ethanolic leaves extract of *Paulinia pinnata* linn (Sapindaceae),” *Nigerian Journal of Pharmaceutical Sciences*, vol. 6, no. 2, pp. 67–72, 2007.

[31] M. O. Falade, D. O. Akinboye, G. O. Gbotoho et al., “In vitro and in vivo antimalarial activity of ficus thornnigii blume (Moraceae) and *lophira alata* banks (Ochnaceae), identified from the ethnomedicine of the nigerian middle belt,” *Journal of Parasitology Research*, vol. 2014, Article ID 972853, 2014.

[32] M. Builders, N. Wannang, and J. Aguiyi, “Antiplasmodial activities of *Parkia biglobosaleaves: In vivo and In vitro studies*,” *Annals of Biological Research*, vol. 2, no. 4, pp. 8–20, 2011.

[33] M. Chinchilla, O. M. Guerrero, G. Abarca, M. Barrios, and O. Castro, “An in vivo model to study the anti-malaric capacity of plant extracts,” *Revista de Biología Tropical*, vol. 46, no. 1, pp. 35–39, 1998.

[34] E. Deharo, G. Bourdy, C. Quenevo, V. Muñoz, G. Ruiz, and M. Sauvain, “A search for natural bioactive compounds in Bolivia through a multidisciplinary approach. Part V. Evaluation of the antimalarial activity of plants used by the Tacana Indians,” *Journal of Ethnopharmacology*, vol. 77, no. 1, pp. 91–98, 2001.

[35] V. Muñoz, M. Sauvain, G. Bourdy et al., “A search for natural bioactive compounds in Bolivia through a multidisciplinary approach. Part I. Evaluation of the antimalarial activity of plants used by the Chacobo Indians,” *Journal of Ethnopharmacology*, vol. 69, no. 2, pp. 127–137, 2000.